POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for myelofibrosis patients: tasquinimod trial launches
Disease control Recruiting nowThis early-stage trial is testing a drug called tasquinimod, either alone or with the standard drug ruxolitinib, in 33 people with myelofibrosis (a type of bone marrow cancer). The goal is to see if the combination is safe and can help control the disease, especially in patients …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Blood cancer drug bomedemstat tested for Long-Term safety
Disease control Recruiting nowThis study follows about 400 people with certain blood cancers (like essential thrombocythemia and myelofibrosis) who are already taking bomedemstat and benefiting from it. The goal is to collect more information on the drug's long-term safety and how well it controls the disease…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 22, 2026 12:00 UTC
-
New hope for rare blood cancers: first human trial of PRT12396 begins
Disease control Recruiting nowThis early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
New hope for myelofibrosis patients: experimental pill targets resistant disease
Disease control Recruiting nowThis early-stage study tests an experimental oral drug, AJ1-11095, in about 76 adults with myelofibrosis (a type of bone marrow cancer) whose disease has stopped responding to standard JAK2 inhibitor therapy. The main goals are to check the drug's safety, find the best dose, and …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:46 UTC
-
New study to map Real-World care for myelofibrosis and anemia
Knowledge-focused Recruiting nowThis study is a research platform that will follow about 200 people in Germany who have myelofibrosis (a type of bone marrow cancer) and anemia (low red blood cells). It will collect information on the treatments they receive, how their disease changes over time, and their qualit…
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:57 UTC
-
5,000 patients join Long-Term study to unlock mysteries of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term observation of 5,000 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, insurance data, and patient surveys over at least five years to track symptoms, treatments, and how the disease …
Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:04 UTC